JP6704050B2 - 水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物 - Google Patents
水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物 Download PDFInfo
- Publication number
- JP6704050B2 JP6704050B2 JP2018527666A JP2018527666A JP6704050B2 JP 6704050 B2 JP6704050 B2 JP 6704050B2 JP 2018527666 A JP2018527666 A JP 2018527666A JP 2018527666 A JP2018527666 A JP 2018527666A JP 6704050 B2 JP6704050 B2 JP 6704050B2
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- composition
- cognitive impairment
- mild cognitive
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims description 178
- 229910052739 hydrogen Inorganic materials 0.000 title claims description 124
- 239000001257 hydrogen Substances 0.000 title claims description 124
- 208000010877 cognitive disease Diseases 0.000 title claims description 74
- 239000000203 mixture Substances 0.000 title claims description 70
- 208000027061 mild cognitive impairment Diseases 0.000 title claims description 69
- 206010012289 Dementia Diseases 0.000 title claims description 68
- 239000004480 active ingredient Substances 0.000 title claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 57
- 229910052751 metal Inorganic materials 0.000 claims description 33
- 239000002184 metal Substances 0.000 claims description 33
- 229910001092 metal group alloy Inorganic materials 0.000 claims description 29
- 239000010419 fine particle Substances 0.000 claims description 17
- 239000000969 carrier Substances 0.000 claims description 16
- 230000003920 cognitive function Effects 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 108700028369 Alleles Proteins 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 5
- 230000003936 working memory Effects 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000007789 gas Substances 0.000 description 40
- 238000000034 method Methods 0.000 description 34
- 239000011347 resin Substances 0.000 description 28
- 229920005989 resin Polymers 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 22
- 208000024827 Alzheimer disease Diseases 0.000 description 12
- 108010060219 Apolipoprotein E2 Proteins 0.000 description 12
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 12
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 101150037123 APOE gene Proteins 0.000 description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 229910001882 dioxygen Inorganic materials 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000011777 magnesium Substances 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 230000007596 spatial working memory Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 239000011261 inert gas Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000003994 anesthetic gas Substances 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229910019440 Mg(OH) Inorganic materials 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- -1 metal hydride compound Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000013918 Apolipoproteins E Human genes 0.000 description 4
- 108010025628 Apolipoproteins E Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000012159 carrier gas Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001755 vocal effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 230000006999 cognitive decline Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910012375 magnesium hydride Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 101710093560 34 kDa protein Proteins 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000013842 nitrous oxide Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Description
[1] 水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物。
[2] 組成物が水素を含む液体である、[1]の軽度認知障害又は認知症の予防又は治療用組成物。
[3] 水素分子が飽和状態で含まれる、[2]の軽度認知障害又は認知症の予防又は治療用組成物。
[4] 組成物が水素ガスである、[1]の軽度認知障害又は認知症の予防又は治療用組成物。
[5] 水素ガスを1〜4%(v/v)の濃度で含む、[4]の軽度認知障害又は認知症の予防又は治療用組成物。
[6] 組成物が水素を吸蔵し保持している、あるいは水素を発生させる金属又は金属合金の微粒子である、[1]の軽度認知障害又は認知症の予防又は治療用組成物。
[7] 医薬組成物である、[1]〜[6]のいずれかの軽度認知障害又は認知症の予防又は治療用組成物。
[8] 健康食品である、[1]〜[3]のいずれかの軽度認知障害又は認知症の予防又は治療用組成物。
[9] 健康食品が水素水である、[8]の軽度認知障害又は認知症の予防又は治療用組成物。
[10] 軽度認知障害の被験体の認知機能を改善するための、[1]〜[9]のいずれかの軽度認知障害又は認知症の予防又は治療用組成物。
[11] 軽度認知障害の認知症への進行を予防する、[1]〜[10]のいずれかの軽度認知障害又は認知症の予防又は治療用組成物。
[12] 作業記憶(ワーキングメモリー)の低下を抑制する、[1]〜[9]のいずれかの軽度認知障害又は認知症の予防又は治療用組成物。
[13] ApoEε4対立遺伝子保有者に用いるための、[1]〜[12]のいずれかの軽度認知障害又は認知症の予防又は治療用組成物。
1.記憶障害の訴えが本人または家族から認められている。
2.日常生活動作は正常。
3.全般的認知機能は正常。
4.年齢や教育レベルの影響のみでは説明できない記憶障害が存在する。
5.認知症ではない。
MgH2+2X→Mg+2H+2X→Mg+2XH
MgH2+2H2O→Mg(OH)2+2H2
利根プロジェクト(茨城県利根町の65歳以上の在住人を対象とし、認知症前駆状態、うつ状態の疫学調査を行うプロジェクト。気分状態、認知機能、身体機能などを評価し、認知症の危険因子を明らかにし、認知機能低下の防御可能性を検討し、認知症予防の可能性を検討することを目的としている。文献:Miyamoto M, Kodama C, Kinoshita T, Yamashita F, Hidaka S, Mizukami K, Kakuma T, Asada T (2009) Dementia and mild cognitive impairment among non-responders to a community survey. J Clin Neurosci 16, 270-276., Bun S, Ikejima C, Kida J, Yoshimura A, Lebowitz AJ, Kakuma T, Asada T (2015) A combination of supplements may reduce the risk of Alzheimer's disease in elderly Japanese with normal cognition. J Alzheimers Dis 45, 15-25.)において軽度認知障害と診断された73人を無作為に2群に分類した。35人には、一日500mLの水素水(1.2ppm)を38人には一日500mLのプラセボ水を与えた。プラセボ水は、水素を溶解する以前の水を用い、パッケージも水素水と同じくし、水素水とプラセボ水の区別がつかないようにして、二重盲検とした。飲まなかった水は回収し、一日平均の飲んだ量を推定した。その結果、水素水もプラセボ水も飲んだ量の一日平均は、300mLであった。
人間では、ApoE遺伝子には対立遺伝子がありApoE4が、動脈硬化やアルツハイマー型認知症のリスクになることが知られている。一方、マウスでは、APOE遺伝子の欠損が同様に認知症や動脈硬化のモデル動物として知られている(それぞれ、Ohsawa I. et al., J Neurosci. 2008;28:6239-6249、Ohsawa I. et al., Biochem Biophys Res Commun. 2008;377:1195-1198)。マウスの認知症モデルを用いて空間作業記憶(ワーキングメモリー)の測定を行った。さらに、分子状水素(H2)の摂取法として、水素水のみならず、水素ガス、および水素発生素材においても効果があるかどうか、マウスを用いて調べた。
野生型はBALB/cCrSlc、APOE遺伝子欠損マウスとして、BALB/c.KOR/StmSlc-ApoeShlを用いた。このマウス系統は、自然発症ApoE欠損マウスである(http://www.jslc.co.jp/inform/shl_basic_data.pdf#search=%27C.KOR%2FStmSlcApoe+shl%27)。
認知機能の程度は、Y迷路試験によって行った(Conrad CD. et al., Brain Res. 1997;759:76-83)。原理は以下の通りである。Y字型の3つのアームの中央に動物を置くと、しばらくしてから探索行動を行う。正常な動物は、いったん探索したアームに戻ることはあまりせず、迷路の外に見え目印を頼りに異なるアームを次々に探索していく。しかし、空間認知・記憶が弱くなったモデル動物では、同じところに何度も入ったり、1つ前に入ったアームに再度はいったりしてしまう。Y迷路試験では、動物が一定の時間に間にどのような順番でアームに入ったかどうかを計測し、3回連続した順番を見ていき、すべて異なるアームへ進入した数の割合(交替反応=percent alternation)を求め、空間認知・記憶の指標とする。
(1)水素水の自由摂取
飽和水素水をガラス容器にいれボールベアリング2個をいれた飲み口から自由摂取させた。飲み口にボールベアリングを2個いれた飲み口からは、水素が容易に抜け出ないようになっている。対象として、水素を溶解する前の原水を同じ容器にいれ、自由摂取させた。水素水と対象水は、週に5回新鮮な水と交換した。
(2)MgH2含有食餌の自由摂取
MgH2は、水と反応すると水素を発生する(MgH2+2H2O→2H2+Mg(OH)2)。MF粉末飼料(オリエンタル酵母製)1 kgあたり0.1gのMgH2を含む粉末飼料を作製し、自由摂取させた。これは、100%MgH2として維持され、100%マウス体内で水素が発生すると仮定すると、水素水の10倍にあたる水素が摂取できる計算に基づく。対象飼料は、1 kgMF粉末飼料あたり0.22gのMg(OH)2を含む飼料とした。飼料は、週に5回新鮮な飼料と交換した。
(3)水素ガスの吸入
マウスを2%水素ガス、98%空気のチャンバーにいれ、週に5回、1時間放置することによって、水素ガスを1時間吸入させた。対象は、空気をいれたチャンバーに週に5回1時間いれた。
週齢8週間から水素又は対象物を摂取させ250日後(10月齢時)にY迷路により空間作業記憶(ワーキングメモリー)を調べた(図4)。APOE遺伝子欠損マウスでは、野生型マウスに比べ、空間作業記憶が低下していた。
2 水素ガスを含む容器
3 酸素ガス、不活性ガス、空気及び麻酔ガスからなる群から選択される少なくとも1種のガスを含む容器
4 配管
Claims (12)
- ApoEε4対立遺伝子保有者に用いるための、水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物。
- 組成物が水素を含む液体である、請求項1記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 水素分子が飽和状態で含まれる、請求項2記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 組成物が水素ガスである、請求項1記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 水素ガスを1〜4%(v/v)の濃度で含む、請求項4記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 組成物が水素を吸蔵し保持している、あるいは水素を発生させる金属又は金属合金の微粒子である、請求項1記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 医薬組成物である、請求項1〜6のいずれか1項に記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 健康食品である、請求項1〜3のいずれか1項に記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 健康食品が水素水である、請求項8記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 軽度認知障害の被験体の認知機能を改善するための、請求項1〜9のいずれか1項に記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 軽度認知障害の認知症への進行を予防する、請求項1〜10のいずれか1項に記載の軽度認知障害又は認知症の予防又は治療用組成物。
- 作業記憶(ワーキングメモリー)の低下を抑制する、請求項1〜9のいずれか1項に記載の軽度認知障害又は認知症の予防又は治療用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016138793 | 2016-07-13 | ||
JP2016138793 | 2016-07-13 | ||
PCT/JP2017/025575 WO2018012596A1 (ja) | 2016-07-13 | 2017-07-13 | 水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2018012596A1 JPWO2018012596A1 (ja) | 2019-05-09 |
JP6704050B2 true JP6704050B2 (ja) | 2020-06-03 |
Family
ID=60953101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018527666A Active JP6704050B2 (ja) | 2016-07-13 | 2017-07-13 | 水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20200196637A1 (ja) |
EP (1) | EP3485892B1 (ja) |
JP (1) | JP6704050B2 (ja) |
CN (1) | CN109475575A (ja) |
WO (1) | WO2018012596A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023055198A1 (ko) * | 2021-09-30 | 2023-04-06 | 한국한의학연구원 | 반하, 대추, 감초, 인삼, 건강, 황금 및 황련 혼합 추출물을 유효성분으로 포함하는, 알츠하이머 치료용 조성물 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6395774B2 (ja) * | 2016-08-24 | 2018-09-26 | MiZ株式会社 | 水素ガスからなる認識機能低下抑制剤 |
CN112004542A (zh) * | 2018-02-23 | 2020-11-27 | MiZ株式会社 | 用于治疗和/或预防认知障碍或痴呆症的组合物 |
JP6762620B2 (ja) * | 2018-07-06 | 2020-09-30 | MiZ株式会社 | 水素ガスからなる認識機能低下抑制剤 |
EP4011397A4 (en) * | 2019-08-07 | 2023-09-27 | National University Corporation Tokyo Medical and Dental University | AGENTS FOR PREVENTING OR TREATING MILD COGNITIVE IMPAIRMENT |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080046177A (ko) | 2005-08-19 | 2008-05-26 | 시게오 오타 | 생체 내의 유해한 활성 산소 및/또는 프리 라디칼 제거제 |
JP2009114084A (ja) * | 2007-11-02 | 2009-05-28 | Shigeo Ota | 水素分子を含む神経新生を促進する組成物 |
CN101951929A (zh) * | 2007-12-28 | 2011-01-19 | 水株式会社 | 用于治疗或预防的外用剂 |
WO2010077730A2 (en) * | 2008-12-09 | 2010-07-08 | Auspex Pharmaceutical, Inc | Indanone inhibitors of acetylcholinesterase |
WO2012111834A1 (ja) * | 2011-02-17 | 2012-08-23 | バイオコーク技研株式会社 | 水素を発生する組成物 |
JP2013146373A (ja) * | 2012-01-19 | 2013-08-01 | Tatsunori Yamaji | 水素生成装置 |
JP2013253036A (ja) * | 2012-06-07 | 2013-12-19 | Kracie Home Products Ltd | 血行促進剤、発汗促進剤及び浴用組成物 |
JP5228142B1 (ja) * | 2012-11-26 | 2013-07-03 | ミズ株式会社 | 生体用高濃度水素ガス供給装置 |
DK3119911T3 (da) * | 2014-03-21 | 2023-10-30 | Alzheon Inc | Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter |
JP6562338B2 (ja) | 2015-01-27 | 2019-08-21 | 学校法人立命館 | 静電容量測定システム、及び、センサユニット |
-
2017
- 2017-07-13 WO PCT/JP2017/025575 patent/WO2018012596A1/ja unknown
- 2017-07-13 US US16/316,902 patent/US20200196637A1/en not_active Abandoned
- 2017-07-13 JP JP2018527666A patent/JP6704050B2/ja active Active
- 2017-07-13 CN CN201780043383.2A patent/CN109475575A/zh active Pending
- 2017-07-13 EP EP17827719.0A patent/EP3485892B1/en active Active
-
2020
- 2020-10-21 US US17/076,165 patent/US20210037858A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023055198A1 (ko) * | 2021-09-30 | 2023-04-06 | 한국한의학연구원 | 반하, 대추, 감초, 인삼, 건강, 황금 및 황련 혼합 추출물을 유효성분으로 포함하는, 알츠하이머 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
WO2018012596A1 (ja) | 2018-01-18 |
US20210037858A1 (en) | 2021-02-11 |
EP3485892B1 (en) | 2021-10-13 |
CN109475575A (zh) | 2019-03-15 |
EP3485892A1 (en) | 2019-05-22 |
US20200196637A1 (en) | 2020-06-25 |
EP3485892A4 (en) | 2020-03-11 |
JPWO2018012596A1 (ja) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6704050B2 (ja) | 水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物 | |
Blomgren et al. | Free radicals, mitochondria, and hypoxia–ischemia in the developing brain | |
US5597585A (en) | Vitamin/mineral composition | |
EP0644760A1 (en) | Treatments for diseases characterized by neovascularization | |
JP2008156320A (ja) | 抗酸化性機能水 | |
US11039992B2 (en) | Stable redox compositions and methods of use | |
JP2009114084A (ja) | 水素分子を含む神経新生を促進する組成物 | |
Wang et al. | Engineered inhaled nanocatalytic therapy for ischemic cerebrovascular disease by inducing autophagy of abnormal mitochondria | |
TW212832B (en) | Improved peroxide disinfection method and devices therefor | |
WO2005070438A1 (en) | Pharmaceutical composition comprising water depleted of heavy isotopes 0-17 and 0-18 | |
CN103834721A (zh) | 一种细胞色素p450 cyp3a4 snp的检测试剂盒 | |
JPWO2018021435A1 (ja) | 水素を有効成分として含む運動持久力を向上させ、又は運動後の疲労感を軽減させる組成物 | |
CN109310957A (zh) | 具有抗氧化及微尘堆积抑制功能的水素水的制备装置、方法以及利用其制备的水素水 | |
Levina et al. | Antisense oligonucleotides immobilized on silicon-organic nanoparticles as a tool for prolonged correction of hypertensive states | |
GB2418855A (en) | Pharmaceutical grade ethyl lactate composition | |
Nishida et al. | Biphasic contraction of isolated guinea pig tracheal chains by superoxide radical | |
US10668027B1 (en) | Method of treating Acanthamoeba infection using allopurinol | |
JP2021138678A (ja) | 遺伝子疾患を予防および/または改善するための分子状水素含有組成物 | |
CN114272260B (zh) | 一种海洋天然产物解酒保肝口服液、制备方法以及应用 | |
JP2021080239A (ja) | 細胞内小器官のヒドロキシルラジカルを消去する分子状水素 | |
JP3231242U (ja) | 高濃度溶存酸素水の合成装置 | |
RU2672066C1 (ru) | Способ прогнозирования скорости роста детей раннего возраста | |
EP0914091B1 (en) | Ethene containing solutions and use thereof in methods of therapy or prophylaxis | |
Petre et al. | Short stature in association with Cornelia de Lange syndrome–it is useful to administrate rhgh? | |
CN117281829A (zh) | 储氢复合金属有机框架及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200422 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200511 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6704050 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |